# OnCo record paper-transform-liso-cel-lancet-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-transform-liso-cel-lancet-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-transform-liso-cel-lancet-2022" ;
  schema:name "TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma"@en ;
  schema:description "In TRANSFORM, a second CD19 CAR-T, lisocabtagene maraleucel, also beat chemotherapy-plus-transplant as second-line treatment, with a low rate of severe side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-transform-liso-cel-lancet-2022/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=TRANSFORM%20lisocabtagene%20maraleucel%20second-line%20Kamdar%20Lancet%202022>, <https://clinicaltrials.gov/study/NCT03575351> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(22)00662-6> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Kamdar M, Solomon SR, Arnason J, et al." ;
  onco:related <https://onco.cc/pairings/car-t-before-transplant-lbcl/>, <https://onco.cc/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/>, <https://onco.cc/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/efs/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:trials <https://onco.cc/trials/transform/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/belinda/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/lancet/> .